

Truth in Testimony Disclosure Form

In accordance with Rule XI, clause 2(g)(5)* of the *Rules of the House of Representatives*, witnesses are asked to disclose the following information. Please complete this form electronically by filling in the provided blanks.

Committee: Energy and Commerce

Subcommittee: Oversight and Investigations

Hearing Date: 09/22/2021

Hearing Title :

Putting Kids First: Addressing COVID-19's Impacts on Children

Witness Name: Margaret G. Rush, MD, MMHC

Position/Title: President, Monroe Carell Jr. Children's Hospital at Vanderbilt

Witness Type: Governmental Non-governmental

Are you representing yourself or an organization? Self Organization

If you are representing an organization, please list what entity or entities you are representing:

I will be principally representing Monroe Carell Jr. Children's Hospital at Vanderbilt and Vanderbilt University Medical Center. I will also be speaking on behalf of members of the Children's Hospital Association.

FOR WITNESSES APPEARING IN A NON-GOVERNMENTAL CAPACITY

Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.

Are you a fiduciary—including, but not limited to, a director, officer, advisor, or resident agent—of any organization or entity that has an interest in the subject matter of the hearing? If so, please list the name of the organization(s) or entities.

Member of the Board, Children's Hospital Alliance of TN
Member of the Board, Vanderbilt Health Affiliated Network
Member of the Board, Vanderbilt Integrated Partners Mid-South, LLC
Member of the Board, Vanderbilt-Williamson Medical Center Clinics, LLC

Please list any federal grants or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you, the organization(s) you represent, or entities for which you serve as a fiduciary have received in the past thirty-six months from the date of the hearing. Include the source and amount of each grant or contract.

A list of federal awards and subawards related to COVID-19 made to Vanderbilt University Medical Center (VUMC) is enclosed. Monroe Carell Jr. Children's Hospital at Vanderbilt is a facility within the larger VUMC.

Please list any contracts, grants, or payments originating with a foreign government and related to the hearing's subject that you, the organization(s) you represent, or entities for which you serve as a fiduciary have received in the past thirty-six months from the date of the hearing. Include the amount and country of origin of each contract or payment.

None.

Please complete the following fields. If necessary, attach additional sheet(s) to provide more information.

- I have attached a written statement of proposed testimony.
- I have attached my curriculum vitae or biography.

* Rule XI, clause 2(g)(5), of the U.S. House of Representatives provides:

(5)(A) Each committee shall, to the greatest extent practicable, require witnesses who appear before it to submit in advance written statements of proposed testimony and to limit their initial presentations to the committee to brief summaries thereof.

(B) In the case of a witness appearing in a non-governmental capacity, a written statement of proposed testimony shall include— (i) a curriculum vitae; (ii) a disclosure of any Federal grants or contracts, or contracts, grants, or payments originating with a foreign government, received during the past 36 months by the witness or by an entity represented by the witness and related to the subject matter of the hearing; and (iii) a disclosure of whether the witness is a fiduciary (including, but not limited to, a director, officer, advisor, or resident agent) of any organization or entity that has an interest in the subject matter of the hearing.

(C) The disclosure referred to in subdivision (B)(iii) shall include— (i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government.

(D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form 24 hours before the witness appears to the extent practicable, but not later than one day after the witness appears.

False Statements Certification

Knowingly providing material false information to this committee/subcommittee, or knowingly concealing material information from this committee/subcommittee, is a crime (18 U.S.C. § 1001). This form will be made part of the hearing record.



Witness signature

Sept 17, 2021

Date

Vanderbilt University Medical Center
COVID-19 Awards

Reflects VUMC Awards Data as of 09/13/2021, p. 10-25

Funding Type	Division	Award Number	Project Status	Direct Sponsor	Prime Sponsor	Title	Budget Start Date	Budget End Date	Budget Total Dollars
New	AIDS Center	M21047-001	Ended	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Vanderbilt CTU SARS-CoV-2 Supplement	06/02/2020	11/30/2020	558,406
	AIDS Center	M21744-001	Active	Family Health International	National Institute of Allergy and Infectious Diseases	HPTN 083 Protocol Funding	05/01/2020	08/31/2020	13,272
	AIDS Center	M21744-001	Active	Family Health International	National Institute of Allergy and Infectious Diseases	HPTN 083 Protocol Funding	05/01/2020	02/28/2021	-8,814
	AIDS Center	M24251-001	Active	University of California Los Angeles	National Institute of Allergy and Infectious Diseases	ACTG Year 14 (COVID-19 funds)	06/01/2020	11/30/2020	176,269
	AIDS Center	M24251-001	Active	University of California Los Angeles	National Institute of Allergy and Infectious Diseases	ACTG Year 15 Fixed Accrual Protocol Funds	12/01/2020	11/30/2021	459,159
	AIDS Center	M26117-001	Active	Family Health International	National Institute of Allergy and Infectious Diseases	FHI HPTN CoVPN Funding	07/01/2020	11/30/2021	363,713
	AIDS Center	M26276-001	Ended	Family Health International	National Institute of Allergy and Infectious Diseases	HPTN Unanticipated Clinical Trial Cost Funds	06/01/2020	11/15/2020	45,537
	AIDS Center	M26097-001	Ended	Fred Hutchinson Cancer Research Center	National Institute of Allergy and Infectious Diseases	HVTN 405/HPTN 1301 COVID Study	06/01/2020	11/30/2020	74,494
	AIDS Center	M26195-001	Active	Fred Hutchinson Cancer Research Center	National Institute of Allergy and Infectious Diseases	CoVPN 3001 Protocol Funding (FF) - Implementation Fund (Year 2)	12/01/2020	11/30/2021	263,855
	AIDS Center	M26198-001	Active	Fred Hutchinson Cancer Research Center	National Institute of Allergy and Infectious Diseases	COVID-19 Prevention Network (CoVPN) Site Prep	07/01/2020	11/30/2021	413,520
	AIDS Center	M26380-001	Active	Fred Hutchinson Cancer Research Center	National Institute of Allergy and Infectious Diseases	CoVPN 3502 Regeneration Phase III Protocol Funding	08/01/2020	11/30/2021	75,640
	AIDS Center	M26970-001	Active	Fred Hutchinson Cancer Research Center	National Institute of Allergy and Infectious Diseases	HVTN 3006 COVID Study	04/15/2021	11/30/2021	443,191
	Anesthesiology	M26758-001	Ended	Massachusetts General Hospital	National Institute on Aging	Maximizing Treatment of Neurological Dysfunction using Intravenous Guanfacine (MENDING)	08/01/2020	05/31/2021	423,737
	Biomedical Informatics	M27071-001	Active	Weill Medical College of Cornell University	Patient-Centered Outcomes Research Institute	Evaluating the Comparative Effectiveness of Telemedicine in Primary Care: Learning from the COVID-19 Pandemic	01/01/2021	10/31/2021	57,913
	Biomedical Informatics	M25925-001	Ended	National Science Foundation	National Science Foundation	RAPID Collaborative: A Privacy Risk Assessment Framework for Person-Level Data Sharing During Pandemics	05/14/2020	04/30/2021	99,999
	Biomedical Informatics	M27249-001	Active	Harvard Pilgrim Health Care	Food and Drug Administration	RWE: Advancing Scalable Natural Language Processing Approaches for Unstructured Electronic Health Record Data	02/01/2021	01/31/2023	932,860
	Biostatistics	M26576-001	Active	Mount Sinai School of Medicine	National Cancer Institute	SARS-CoV-2 Serological Science Centers of Excellence (USA)-Data Science Core	09/03/2020	08/31/2021	206,790
	Biostatistics	M26576-001	Active	Mount Sinai School of Medicine	National Cancer Institute	Vulnerability of SARS-CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses - Core 2-Data Science Core	09/01/2021	08/31/2022	214,420
	Cancer Center (VIOC)	M21562-001	Ended	National Cancer Institute	National Cancer Institute	COVID-19 Pandemic and Its Effects Within the Southern Community Cohort Study	07/01/2020	06/30/2021	172,883
	Cancer Center (VIOC)	M21262-001	Ended	National Cancer Institute	National Cancer Institute	COVID-19 and Cancer Consortium (CCC19)	09/01/2019	08/31/2020	595,000
	Cancer Center (VIOC)	M26221-001	Active	National Cancer Institute	National Cancer Institute	The COVID-19 and Cancer Consortium: NCI Administrative Supplement to P30 Cancer Center Support Grant (CCSG)	05/01/2021	08/31/2021	600,000
	Emergency Medicine	M25748-001	Ended	Duke University	Patient-Centered Outcomes Research Institute	Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCO Trial)	04/01/2020	01/31/2021	840,500
	Emergency Medicine	M25828-001	Ended	Duke Clinical Research Institute	Patient-Centered Outcomes Research Institute	HERO Steering Committee	04/01/2020	03/31/2021	5,000
	Emergency Medicine	M26487-001	Ended	Aerie Pharmaceuticals, Inc.	U.S. Army Medical Research Acquisition Activity	Safety and Efficacy of Raluzorafinib in Hospitalized Subjects with Moderate to Severe Coronavirus Disease 2019 (COVID-19) (RESCUE Study)	12/11/2020	03/01/2021	338,748
	Emergency Medicine	M25839-001	Ended	Massachusetts General Hospital	National Heart, Lung, and Blood Institute	Outcomes Related to COVID-19 treated with Hydroxychloroquine among inpatients with symptomatic Disease	04/15/2020	01/14/2021	177,486
	Emergency Medicine	M26635-001	Active	Centers For Disease Control and Prevention (CDC)	Centers For Disease Control and Prevention (CDC)	Evaluations of Mission Act Section 152. Pilot and COVID-19 recovery	02/05/2021	02/04/2022	13,480,835
	Health Policy	M26877-001	Active	Veterans Medical Research Foundation	Veterans Medical Research Foundation	Household Transmission of Influenza Viruses in the Community-COVID-19 Supplement	04/01/2021	03/31/2022	24,206
	Health Policy	M22812-001	Ended	Centers For Disease Control and Prevention (CDC)	Centers For Disease Control and Prevention (CDC)	Routine Care during COVID-19 pandemic for Low-income Older Adults with Diabetes and Dementia	09/01/2019	08/31/2020	500,000
	Health Policy	M26155-001	Active	National Institute on Aging	National Institute on Aging	SURVEILLANCE SERVICES (EMERGING INFECTIOUS DISEASES PROGRAM)-COVID 19 Supplement	04/01/2021	04/30/2021	111,149
	Health Policy	014563-001	Active	Tennessee Department of Health Services	Centers For Disease Control and Prevention (CDC)	Partnership for Research in Emerging Viral Infections-Sierra Leone (PREVISE)-COVID Supplement	01/01/2020	12/31/2020	1,800,000
	Institute for Global Health	M24918-001	Active	John E. Fogarty International Center	John E. Fogarty International Center	ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications	08/20/2021	07/31/2022	75,000
	Institute of Medicine and Public Health	M27054-001	Active	Duke University	National Center for Advancing Translational Sciences	Greenlight Plus Study: A Randomized Study Of Approaches To Early Childhood Obesity Prevention-Covid-19 Supplement	04/17/2021	06/30/2023	237,000
	Institute of Medicine and Public Health	M24633-001	Active	Patient-Centered Outcomes Research Institute	Patient-Centered Outcomes Research Institute		07/01/2020	02/28/2021	418,857

	Institute of Medicine and Public Health	M26988-001	Active	State of Tennessee	Centers for Medicare and Medicaid Services	Quality Improvement Collaborative for COVID-19 Prevention and Control in Middle Tennessee Nursing Homes	05/01/2021	06/30/2021	112,900
	Institute of Medicine and Public Health	M26988-001	Active	State of Tennessee	Centers for Medicare and Medicaid Services	Quality Improvement Collaborative for COVID-19 Prevention and Control in Middle Tennessee Nursing Homes	07/01/2021	06/30/2022	671,700
	Institute of Medicine and Public Health	M25751-001	Ended	Duke Clinical Research Institute	Patient-Centered Outcomes Research Institute	Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial "HERO HCO Trial"-Steering Committee	04/01/2020	03/31/2021	7,500
	Institute of Medicine and Public Health	M25886-001	Active	Patient-Centered Outcomes Research Institute	Patient-Centered Outcomes Research Institute	Advancement of PCORnet Infrastructure: Clinical Research Network Project-Cost Extension and COVID-19 Supplement	08/01/2021	12/31/2021	844,751
	Institute of Medicine and Public Health	M25886-001	Active	Patient-Centered Outcomes Research Institute	Patient-Centered Outcomes Research Institute	Advancement of PCORnet Infrastructure: Clinical Research Network Project-Cost Extension and COVID-19 Supplement	10/01/2020	12/31/2021	2,258,799
	Institute of Medicine and Public Health	M25238-001	Ended	Duke Clinical Research Institute	Patient-Centered Outcomes Research Institute	Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial "HERO HCO Trial"-CRN support agreement	04/01/2020	01/01/2021	28,000
	Institute of Medicine and Public Health	M26604-001	Ended	The Task Force for Global Health	Centers For Disease Control and Prevention (CDC)	COVID-19 Electronic Healthcare Data Initiative	10/01/2020	07/31/2021	86,500
	Medicine/Allergy Pulmonary & Critical Care	M24605-001	Active	National Institute on Aging	National Institute on Aging	BRAIN-2 Administrative Supplement with ORCHID-BUD	04/29/2020	01/31/2021	424,819
	Medicine/Allergy Pulmonary & Critical Care	M24605-001	Active	National Institute on Aging	National Institute on Aging	BRAIN-2 COVID-19 Administrative Supplement	09/01/2020	01/31/2021	888,245
	Medicine/Allergy Pulmonary & Critical Care	M24605-001	Active	National Institute on Aging	National Institute on Aging	BRAIN-2 Study: Bringing to Light the Risk Factors and Incidence of Neuropsychological Dysfunction (Dementia) in ICU Survivors, 2nd Study	02/01/2021	01/31/2022	3,630,964
	Medicine/Allergy Pulmonary & Critical Care	M26498-001	Active	Congressionally Directed Medical Research Programs	Congressionally Directed Medical Research Programs	Addressing Post-Intensive Care Syndrome among Survivors of Acute Lung Injury with COVID-19	01/15/2020	01/14/2024	760,307
	Medicine/Allergy Pulmonary & Critical Care	M21464-001	Ended	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Viral and Host Determinants of Infant and Childhood Allergy and Asthma.DCC	08/01/2020	07/31/2021	1,550,210
	Medicine/Allergy Pulmonary & Critical Care	M21464-001	Ended	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Viral and Host Determinants of Infant and Childhood Allergy and Asthma (HEROS 2)	12/14/2020	07/31/2021	164,815
	Medicine/Allergy Pulmonary & Critical Care	M25893-001	Ended	Massachusetts General Hospital	Department of Health and Human Services	Outcomes Related to COVID-19 treated with hydroxychloroquine among in-patients with symptomatic disease (ORCHID)	04/14/2020	07/23/2020	3,217,025
	Medicine/Allergy Pulmonary & Critical Care	M26351-001	Active	Massachusetts General Hospital	National Heart, Lung, and Blood Institute	Biology and Longitudinal Epidemiology of COVID-19 Observational Study, BLUE CORAL	04/24/2020	04/23/2022	111,750
	Medicine/Allergy Pulmonary & Critical Care	M26355-001	Ended	Massachusetts General Hospital	National Heart, Lung, and Blood Institute	RED CORAL: PETAL COVID-19 Observational Study	04/24/2020	04/23/2021	138,000
	Medicine/Allergy Pulmonary & Critical Care	M26361-001	Active	Massachusetts General Hospital	National Heart, Lung, and Blood Institute	PETAL Network International Coordinating Center for ACTIV-3 Trial Initiative	06/01/2020	05/31/2021	718,750
	Medicine/Allergy Pulmonary & Critical Care	M26377-001	Active	Massachusetts General Hospital	National Heart, Lung, and Blood Institute	PETAL Network International Coordinating Center for ACTIV-3 Trial Initiative	06/01/2021	05/31/2022	180,000
	Medicine/Allergy Pulmonary & Critical Care	M27056-001	Active	Massachusetts General Hospital	National Heart, Lung, and Blood Institute	PETAL COVID-19 Observational Study	04/24/2020	04/23/2022	7,560
	Medicine/Allergy Pulmonary & Critical Care	M22442-001	Active	National Heart, Lung, and Blood Institute	National Heart, Lung, and Blood Institute	PETAL Network ICC for ACTIV-3 "Therapies for Severely Ill Inpatients with COVID-19 (TESICO)"	01/01/2021	05/31/2022	687,000
	Medicine/Cardiovascular Medicine	M26726-001	Ended	University of Manitoba	National Heart, Lung, and Blood Institute	Mechanisms of airspace inflammation caused by cell-free hemoglobin during ARDS	09/10/2021	03/09/2022	131,436
	Medicine/Cardiovascular Medicine	M26726-001	Ended	University of Manitoba	National Heart, Lung, and Blood Institute	Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)	11/24/2020	05/31/2021	231,650
	Medicine/Internal Medicine	M26121-001	Active	University of Wisconsin Madison	National Cancer Institute	Investigating the Association between Smoking Status and COVID-19 Outcomes: Collecting Data from Health Systems Affiliated with the National Cancer Institute's Cancer Center Cessation Initiative (C3I)	06/29/2021	09/28/2021	17,300
	Medicine/Internal Medicine	M26121-001	Active	University of Wisconsin Madison	National Cancer Institute	Investigating the Association between Smoking Status and COVID-19 Outcomes: Collecting Data from Health Systems Affiliated with the National Cancer Institute's Cancer Center Cessation Initiative (C3I)	06/29/2020	06/28/2021	51,900
	Medicine/Geriatrics	M25870-001	Ended	Health Resources and Services Administration	Health Resources and Services Administration	Geriatrics Workforce Enhancement Program COVID	05/01/2020	04/30/2021	90,625
	Medicine/Geriatrics	M21135-001	Ended	National Institute on Minority Health and Health Disparities	National Institute on Minority Health and Health Disparities	Center of Excellence in Precision Medicine and Population Health	07/01/2020	03/31/2021	211,245
	Medicine/Infectious Disease	M26496-001	Active	Centers For Disease Control and Prevention (CDC)	Centers For Disease Control and Prevention (CDC)	Hospital-based Discovery at an Institutional Site: The Pathogenic Determinants of SARS-CoV-2 Disease Manifestations	12/14/2020	12/13/2021	1,856,996
	Medicine/Infectious Disease	M26195-001	Active	Fred Hutchinson Cancer Research Center	National Institute of Allergy and Infectious Diseases	COVFN 3001 Protocol Funding (PF) - Implementation Funds	07/27/2020	11/30/2020	2,737,075
	Medicine/Infectious Disease	M26782-001	Active	Benaroya Research Institute at Virginia Mason	National Institute of Allergy and Infectious Diseases	Immune Tolerance Network	02/01/2021	01/31/2022	711,291

Medicine/Infectious Disease	M26457-001	Ended	Johns Hopkins	National Institute of Allergy and Infectious Diseases	North American AIDS Collaboration on Research and Design (NA-AACCORD)	06/30/2020	13,366
Medicine/Infectious Disease	M26457-001	Ended	Johns Hopkins	National Institute of Allergy and Infectious Diseases	North American AIDS Collaboration on Research and Design (NA-AACCORD)	07/01/2020	86,478
Medicine/Infectious Disease	M21760-001	Ended	Centers For Disease Control and Prevention (CDC)	Centers For Disease Control and Prevention (CDC)	Determining Influenza Vaccine Effectiveness	08/01/2019	500,000
Medicine/Infectious Disease	M27035-001	Active	Centers For Disease Control and Prevention (CDC)	Centers For Disease Control and Prevention (CDC)	9.2: Determining the effectiveness of influenza and COVID-19 vaccines for the prevention of Medically Attended Outpatient Illness	07/01/2021	1,347,111
Medicine/Nephrology	M25232-001	Active	Veterans Administration, Tennessee	Veterans Administration, Tennessee	VA IPA Robert Greewy - Slow	04/01/2021	27,990
Neurology/Immunology	M24049-001	Active	Johns Hopkins University School of Medicine	Patient-Centered Outcomes Research Institute	TRadical versus Early Aggressive Therapy for Multiple Sclerosis (TREA-MS) Trial	12/19/2020	73,524
Nursing Administration	M27177-001	Active	Association of American Medical Colleges	Centers For Disease Control and Prevention (CDC)	Improving Clinical and Public Health Outcomes through National Partnerships to Prevent and Control Emerging and Re-Emerging Infectious Disease Threats	03/01/2021	12,000
Ophthalmology	M22815-001	Active	New York University School of Medicine	National Eye Institute	Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus (COVID)	05/15/2020	5,000
Othopedics and Rehabilitation	M23993-001	Active	Department of Defense	Department of Defense	Effect of early weight bearing on rehabilitation outcomes in patients with unicoronylar proximal tibia fractures and bimalleolar ankle fractures.	06/02/2021	182,036
Otolaryngology	M26519-001	Ended	Columbia University	National Institute on Deafness and Communication Disorders	The Impact of COVID 19 on Voice, Laryngeal Function and Quality of Life	07/01/2020	34,000
Otolaryngology	M25298-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Integrated Metagenomic and Metatranscriptomic Characterization of Inflammatory Chronic Rhinosinusitis Endotypes	06/30/2020	303,897
Otolaryngology	M25298-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Integrated Metagenomic and Metatranscriptomic Characterization of Inflammatory Chronic Rhinosinusitis Endotypes (Ref. M0056833)	01/01/2021	153,029
Pathology	M26754-001	Ended	Vanderbilt University	National Institute of Allergy and Infectious Diseases	Point-of-Care RT-PCR System to Inform COVID-19 and Respiratory Illness Decisions	09/19/2020	340,000
Pediatrics	M23123-001	Active	Health Resources and Services Administration	Health Resources and Services Administration	Emergency Medical Services for Children State Partnership Rural Expansion Program	04/01/2021	163,552
Pediatrics	M26468-001	Ended	Stanford University	National Institute of Allergy and Infectious Diseases	Outcomes and the Immune Response in Allergic Diseases in Pediatric Transplant Recipients	08/10/2020	662,900
Pediatrics/Clinical Research Office	M25249-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Vanderbilt Vaccine and Treatment Evaluation Unit - COVID-19 Supplement	03/25/2020	842,642
Pediatrics/Clinical Research Office	M25249-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older	07/14/2020	12,509,936
Pediatrics/Clinical Research Office	M25249-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Vanderbilt Vaccine and Treatment Evaluation Unit - COVID-19 - 02S1	12/01/2020	192,338
Pediatrics/Clinical Research Office	M25249-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Vanderbilt Vaccine and Treatment Evaluation Unit - 02S2	12/01/2020	4,613,138
Pediatrics/Clinical Research Office	M25249-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Vanderbilt Vaccine and Treatment Evaluation Unit - DMD 21-0002	04/23/2021	614,901
Pediatrics/Clinical Research Office	M25249-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Vanderbilt Vaccine and Treatment Evaluation Unit - KCCOIVE	05/14/2021	5,245,366
Pediatrics/Clinical Research Office	M25249-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Vanderbilt Vaccine and Treatment Evaluation Unit - DMD 21-0012	07/07/2021	2,093,628
Pediatrics/Clinical Research Office	M25249-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Vanderbilt Vaccine and Treatment Evaluation Unit - DMD 21-0004	08/10/2021	698,548
Pediatrics/Clinical Research Office	M25797-001	Active	Emory University	National Institute of Allergy and Infectious Diseases	Leadership Group for an Infectious Diseases Clinical Research Consortium (Plaque-Reduction Neutralization Testing (PRNT) of Sera from Human Recipients of the Moderna COVID-2019 Vaccine)	03/13/2020	230,550
Pediatrics/Clinical Research Office	M26296-001	Ended	Centers For Disease Control and Prevention (CDC)	Centers For Disease Control and Prevention (CDC)	CISA-Clinical Vaccine Safety Evaluation, Lead Site, Task COVID	09/24/2020	1,607,125
Pediatrics/Infectious Disease	M22990-001	Active	University of North Carolina-Chapel Hill	National Institute of Allergy and Infectious Diseases	Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging Cov	05/08/2020	212,500
Pediatrics/Infectious Disease	M22990-001	Active	University of North Carolina-Chapel Hill	National Institute of Allergy and Infectious Diseases	Broad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging Cov	08/01/2021	212,500
Pediatrics/Infectious Disease	M23340-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Determinants of Coronavirus Fidelity in Replication and Pathogenesis	07/06/2020	318,794
Pediatrics/Infectious Disease	M23340-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Determinants of Coronavirus Fidelity in Replication and Pathogenesis	03/01/2021	447,335
Pediatrics/Infectious Disease	M23340-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Determinants of Coronavirus Fidelity in Replication and Pathogenesis	03/01/2021	672,084
Pediatrics/Infectious Disease	M26904-001	Active	Veterans Administration, Tennessee	Veteran's Affairs Medical Center Washington DC	Determinants of Coronavirus Fidelity in Replication and Pathogenesis	04/28/2021	30,000

Pediatrics/Infectious Disease	M21783-001	Active	Centers For Disease Control and Prevention (CDC)	Centers For Disease Control and Prevention (CDC)	Centers For Disease Control and Prevention (CDC)	09/01/2019	08/31/2020	300,000
Pediatrics/Infectious Disease	M21783-001	Active	Centers For Disease Control and Prevention (CDC)	Centers For Disease Control and Prevention (CDC)	Enhanced surveillance for New Vaccine Preventable Disease	09/01/2020	11/30/2021	557,142
Pediatrics/Infectious Disease	M25994-001	Active	Boston Childrens Hospital	Centers For Disease Control and Prevention (CDC)	Understanding COVID-19 among critically ill children in the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network	04/09/2020	05/04/2022	124,400
Pediatrics/Infectious Disease	M26448-001	Active	Boston Childrens Hospital	Centers For Disease Control and Prevention (CDC)	Understanding COVID-19 among critically ill children in the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network (Lab based)	04/09/2020	10/08/2021	139,146
Pediatrics/Infectious Disease	M26916-001	Ended	Johns Hopkins University School of Medicine	Centers For Disease Control and Prevention (CDC)	Enhanced Surveillance for New Vaccine Preventable Diseases	05/01/2020	07/31/2021	191,708
Pediatrics/Infectious Disease	M27290-001	Active	Centers For Disease Control and Prevention (CDC)	Centers For Disease Control and Prevention (CDC)	Enhanced Surveillance for New Vaccine Preventable Diseases	09/01/2021	08/31/2022	1,441,645
Pediatrics/Neonatology	02254-001	Active	State of Tennessee - Bureau of TennCare	Department of Health and Human Services	High Risk Perinatal Program	07/01/2020	06/30/2021	1,139,800
Poison Control Center	M25933-001	Ended	Health Resources and Services Administration	Health Resources and Services Administration	CARES Funding for Poison Centers	04/01/2020	03/31/2021	97,390
Poison Control Center	M22295-001	Active	State of Tennessee	Department of Education	Poison Control, Chemical and Biological Terrorism Incident Tracking	07/01/2019	06/30/2020	200,000
Poison Control Center	M22295-001	Active	State of Tennessee	Department of Health and Human Services	Poison Control, Chemical and Biological Terrorism Incident Tracking, COVID	07/01/2020	06/30/2021	1,295,000
Surgery/Surgical Research	M26051-001	Ended	National Science Foundation	National Science Foundation	RAPID: Coronavirus M protein interaction with Myosin V Exon D	08/01/2020	07/31/2021	200,000
Surgery/Surgical Research	M27127-001	Active	National Institute of Diabetes & Digestive & Kidney Disease	National Institute of Diabetes & Digestive & Kidney Disease	Small GTP Binding Proteins in Gastrointestinal Mucosa	08/01/2021	07/31/2022	633,924
Vanderbilt Comprehensive Care Clinic (V-COC)	019039-001	Active	Metropolitan Nashville & Davidson County	Health Resources and Services Administration	Ryan White Part A Covid-19 Response	12/14/2020	12/13/2021	155,202
Vanderbilt Comprehensive Care Clinic (V-COC)	M25787-001	Ended	Health Resources and Services Administration	Health Resources and Services Administration	Ryan White HIV/AIDS Program Part D WICY COVID-19 Response	04/01/2020	03/31/2021	37,168
Vanderbilt Comprehensive Care Clinic (V-COC)	M25789-001	Ended	Health Resources and Services Administration	Health Resources and Services Administration	Ryan White HIV/AIDS Program Part C EIS COVID-19 Response	04/01/2020	03/31/2021	157,945
Vanderbilt Comprehensive Care Clinic (V-COC)	M25901-001	Ended	Health Resources and Services Administration	Health Resources and Services Administration	Ryan White HIV/AIDS Program AIDS Education and Training Centers Program COVID19	04/01/2020	03/31/2021	400,000
Vanderbilt Kennedy Center(MC)	M26917-001	Active	Administration for Community Living	Administration for Community Living	UCEDD COVID-19 Access	04/01/2021	09/30/2022	59,701
Vanderbilt Vaccine Center	M23197-001	Active	Defense Advanced Research Projects Agency	Defense Advanced Research Projects Agency	RRADD: Rapid Rational Antibody Design and Delivery(VCLIN-0004) (COVID-19 Funding/New)	09/28/2020	12/18/2021	3,995,865
Vanderbilt Vaccine Center	M25264-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Rapid Identification of Human Antibodies and Epitopes for Epitomic 2019-nCoV (PCell Supplement)	02/18/2020	02/17/2021	1,536,726
Vanderbilt Vaccine Center	M25264-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Genetic and Structural Basis for Virus Neutralization (Supplemental Work, Coronavirus, Line Item 5)	09/01/2020	08/31/2021	1,496,863
Vanderbilt Vaccine Center	M26950-001	Ended	Washington University	National Institute of Allergy and Infectious Diseases	Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2	09/15/2020	08/31/2021	384,737
Vanderbilt Vaccine Center	M22563-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Antibody repertoire characterization in the context of coronaviruses	07/28/2020	05/31/2021	675,447
Vanderbilt Vaccine Center	M22563-001	Active	National Institute of Allergy and Infectious Diseases	National Institute of Allergy and Infectious Diseases	Antibody repertoire characterization in the context of coronaviruses	06/01/2021	05/31/2022	673,335
VC Health Affairs	M26153-001	Active	State of Tennessee	Centers For Disease Control and Prevention (CDC)	VUMC Shirke Teams	07/01/2020	12/31/2021	311,084
VC Health Affairs	M26186-001	Ended	Tennessee Department of Health Services	Department of Health and Human Services	Child Care Certificate Program Belcourt	08/10/2020	08/21/2020	302,016
VC Health Affairs	M26188-001	Ended	Tennessee Department of Health Services	Department of Health and Human Services	Child Care Certificate Program Belcourt AMENDMENTS	08/22/2020	08/31/2021	1,100,000
VC Health Affairs	M26189-001	Ended	Tennessee Department of Health Services	Department of Health and Human Services	Child Care Certificate Program Knob	08/10/2020	08/21/2020	220,748
VC Health Affairs	M26190-001	Ended	Tennessee Department of Health Services	Department of Health and Human Services	Child Care Certificate Program Knob AMENDMENTS	08/22/2020	08/31/2021	925,000
VC Health Affairs	M26190-001	Ended	Tennessee Department of Health Services	Department of Health and Human Services	Child Care Certificate Program Patterson	08/10/2020	08/21/2020	244,508
VC Health Affairs	M26944-001	Ended	Tennessee Department of Health Services	Department of Health and Human Services	Child Care Certificate Program Patterson AMENDMENTS	08/22/2020	08/31/2021	925,000
VICTR	M22542-001	Active	National Center for Advancing Translational Sciences	Department of Health and Human Services	Child Care Certificate Program Patterson AMENDMENTS	02/01/2021	09/31/2021	460,000
VICTR	M22542-001	Active	National Center for Advancing Translational Sciences	National Center for Advancing Translational Sciences	Vanderbilt Institute for Clinical and Translational Research (VICTR) (CO2H Supplement)	07/01/2020	02/28/2021	96,461
VICTR	M22542-001	Active	National Center for Advancing Translational Sciences	National Center for Advancing Translational Sciences	Vanderbilt Institute for Clinical and Translational Research (VICTR) - PassiOn Convalescent Plasma Supplement	08/18/2020	02/28/2022	34,000,000
VICTR	M22542-001	Active	National Center for Advancing Translational Sciences	National Center for Advancing Translational Sciences	Vanderbilt Institute for Clinical and Translational Research (VICTR) - Informing convalescent plasma dosing strategies via identification of correlates of functional immunity Supplement	09/16/2020	02/28/2022	562,991
VICTR	M22542-001	Active	National Center for Advancing Translational Sciences	National Center for Advancing Translational Sciences	Vanderbilt Institute for Clinical and Translational Research (VICTR)	03/01/2021	02/28/2022	8,192,144
VICTR	M26067-001	Active	Research Triangle Institute	National Heart, Lung, and Blood Institute	Coordination and Organization of the Networks of Networks for Evaluating COVID-19 Therapeutic Strategies CONNECTS	06/15/2020	05/31/2021	2,071,105

